Q1 FY2025 · ended Sep 30, 2024 · Revenue $522,000, +13.7% YoY · Filed Nov 19, 2024
Renalytix plc (RNLXY) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q1 of fiscal 2025, the quarter ended Sep 30, 2024, it reported revenue of $522,000 and a net loss of $4.7 million. As of Sep 30, 2024 it held $909,000 in cash and investments and $11,500 in total debt.
Revenue
$522,000
+13.7% vs year-ago quarter
Net income
$-4.73M
+53.4% vs year-ago quarter
Operating cash flow
$-3.84M
+59.6% vs year-ago quarter
Free cash flow
—
EPS
$-0.04
+63.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
331.21M
+239.9% vs year-ago quarter
Net cash
$897,500
Q1 FY2025
Operating margin
-1054.9%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- RNLXY (OTC), RENXF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1811115
- Former names
- Renalytix AI plc (until Jun 25, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2025 Sep 30, 2024 |
Q4 FY2024 Jun 30, 2024 |
Q3 FY2024 Mar 31, 2024 |
Q2 FY2024 Dec 31, 2023 |
Q1 FY2024 Sep 30, 2023 |
|---|---|---|---|---|---|
| Revenue | $522,000 | $586,000 | $535,000 | $709,000 | $459,000 |
| Operating income | -$4.1M | -$5.5M | -$6.6M | -$8.6M | -$8.9M |
| Net income | -$4.7M | -$7.1M | -$7.7M | -$8.5M | -$10.2M |
| Diluted EPS | -$0.04 | -$0.05 | -$0.08 | -$0.09 | -$0.11 |
| Operating cash flow | -$3.8M | -$7.8M | -$4.9M | -$7.9M | -$9.5M |
| Total assets | $4.8M | $8.0M | $8.8M | $11.3M | $19.5M |
| Total liabilities | $16.1M | $15.8M | $19.9M | $19.2M | $21.0M |
| Stockholders' equity | -$11.3M | -$7.9M | -$11.1M | -$8.0M | -$1.5M |
| Cash and investments | $909,000 | $4.7M | $4.7M | $5.6M | $13.9M |
| Total debt | $11,500 | $45,000 | $78,000 | $111,000 | $141,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Jan 16, 2025 | Jan 16, 2025 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Dec 20, 2024 | Dec 19, 2024 |
| 8-K/A |
Amended current report
Material agreement, New debt
|
Nov 19, 2024 | Sep 26, 2024 |
| 10-Q | Quarterly report | Nov 19, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Regulation FD disclosure
|
Nov 6, 2024 | Oct 31, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Results of operations, New debt, Listing notice, Unregistered share sale, Other events
|
Oct 1, 2024 | Sep 26, 2024 |
All 233 Renalytix plc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.